



Pharming Group NV

**UBS Global Life Sciences Conference
New York**

September 2010

**Sijmen de Vries, MD, MBA
Chief Executive Officer**

The information contained in this document and made verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purpose.

The Presentation does not form any part of an offer of, or invitation to apply for, securities in Pharming Group N.V. (the "Company").

The Presentation speaks as of its date. The Company assumes no obligation to notify or inform the recipient of any developments or changes occurring such date of this document that might render the contents of the Presentation untrue or inaccurate in whole or in part. In addition, no representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by the Company or any of its directors, members, officers, employees, agents or advisers.

The Presentation contains forward-looking statements, including statements about our beliefs and expectations. These statements are based on our current plans, estimates and projections, as well as our expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties and speak only as of the date they are made. The Company undertakes no duty to and will not necessarily update any of them in light of new information or future events, except to the extent required by applicable law.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.

HEALTH ■ SCIENCE ■ PRODUCTS

About Pharming



- Public biotech company (*NYSE Euronext: PHARM*)
- Headquartered in Leiden (NL)
 - R&D sites in NL and USA
 - 74 FTE
- Strategy is to develop innovative products for orphan diseases with high unmet medical needs
 - Followed by development of subsequent indications where possible
 - Underpinned by proprietary technology (transgenic) platform for protein production
 - Versatile & scalable without typical bio-reactor up-scaling risks
- Current focus on lead product recombinant C1-inhibitor (Ruconest™/ Rhucin®) franchise
- Successful company turnaround in progress (Rhucin rejected by EMA in early 2008)
 - Restructuring balance sheet
 - Streamlining organization to focus on cost savings

Highlights

- EU: Ruconest™ close to market
 - Positive EMA opinion for approval (EU) in June 2010
 - Ruconest EU launch planned for Q4 2010
 - Significant launch inventory available
 - EU distribution partnership with Swedish Orphan Biovitrum
- US: Rhucin®
 - US BLA submission planned for end of year
 - Commercialisation agreement signed with Santarus
- Additional manufacturing agreement with Sanofi Chimie (in addition to MSD)
 - (upscaling for global demand and improving cost of goods)
- Focus:
 - Rec. C1 inhibitor franchise being maximised
 - Spin-out of DNage (early stage anti-aging technology)
- C1INH follow on indications identified & supported by pre-clinical studies

Hereditary Angioedema (HAE)

Significant Impact on Quality of Life



- Genetic disease: partial deficiency or dysfunction of C1 inhibitor
- Patients present with swelling, severe abdominal pain, or acute airway obstruction
- Prevalence of disease estimated at 1 in 30,000
- 8+ swelling episodes requiring treatment per patient per year

- Three systems active in HAE (Complement, Contact, Fibrinolytic)
- C1 inhibitor (missing protein) controls all three systems
- Significant Quality of Life issues for patients given frequent attacks of swelling
- Treatment with C1 inhibitor considered 'gold standard' by patients and allergists/immunologists

HAE Treatment - C1 inhibitor

Complement System



Contact System



Fibrinolytic System



C1INH

Competitive Environment - Peptide Products

Complement System



Contact System



Fibrinolytic System



 DX-88
 Icatibant

* __ * - Sites inhibited by C1INH

Ruconest™ / Rhucin®

- Recombinant Human C1 inhibitor (*INN: Conestat alfa*)
- First indication: Treatment of acute angioedema attacks in patients with hereditary angioedema (HAE)
- Expressed in the milk of transgenic rabbits
 - Well validated cGMP manufacturing process established at CMO
 - Confirmed by EMA review
 - Versatile and scalable platform
 - No evidence of immunogenicity (no HRI Abs or anti-C1INH Abs)
- Clear benefits over competing products



*** Only recombinant replacement therapy in development for HAE ***


Target Product Profile

<u>Attribute</u>	<u>"Target"</u>
<i>Efficacy</i>	<i>Good</i>
<i>Side Effects</i>	<i>Minimal</i> <i>Lack of anaphylaxis</i>
<i>Administration</i>	<i>Home use</i>
<i>Storage</i>	<i>Stable at room temp.</i>

Target Product Profile

<u>Attribute</u>	<u>"Target"</u>	<u>Ruconest/ Rhucin</u>
<i>Efficacy</i>	<i>Good</i>	<i>Excellent</i> <i>90-95% responders</i> <i>No underdosing</i> <i>Label for all locations</i>
<i>Side Effects</i>	<i>Minimal</i> <i>Lack of anaphylaxis</i>	<i>No injection site reactions</i> <i>No anaphylaxis</i>
<i>Administration</i>	<i>Home use</i>	<i>IV</i> <i>Potential home use</i> <i>Liked by emergency docs</i>
<i>Storage</i>	<i>Stable at room temp.</i>	<i>Yes</i>

Market Drivers



1. **Increasing diagnosis/physician awareness**
2. **Patients seeking treatment even for moderate symptoms**
3. **New drug pricing**
 EU: EUR 2000-3400 per attack
 US: USD 5000-7950 per attack

EU Commercialisation Strategy

- Recent distribution partnership with Swedish Orphan Biovitrum for 24 EU markets and Norway, Iceland, Switzerland will allow maximisation of value of Ruconest™ in EU
- €3m upfront and additional approval milestones
- Option to participate in (costs and benefits) of development of future follow-on indications
- Tiered royalty structure to achieve and maintain balanced economics and to create mutually attractive upsides driven by HAE and follow-on indications
- Additional distribution agreements in place for:
 - Spain, Portugal and Greece with Esteve (structure focused on balanced economics)
 - Turkey with Eczasibasi (strong domestic partner)

US Commercialisation Strategy

- Commercialisation agreement with Santarus for North America
- USD 15m upfront and USD 5m at acceptance of BLA
 - Additional clinical regulatory and commercial milestones, including sales level related milestones
 - Sharing (costs and benefits) of development of future follow-on indications
 - Tiered supply price structure to achieve and maintain balanced economics and to create mutually attractive upsides driven by HAE and follow-on indications

Maximizing Value Rec. C1 inhibitor Franchise

Two indications for further development:

- Antibody Mediated Rejection (AMR): rejection after organ transplantation resulting in damage that can lead to organ failure
 - Circulating donor specific Abs leading to complement activation and cell death
- Delayed Graft Function (DGF): most common complication after kidney transplantation
 - Ischaemia reperfusion injury

Status:

- AMR: underpinned by successful pre-clinical results in primate AMR model
 - Initial Phase II study planned for 2010 under active IND
- DGF: underpinned by successful pre-clinical results in DGF swine model
 - Preparations for Phase II study underway

Pipeline

	Indication	R&D	Pre Clinical	Phase I	Phase II	Phase III	Registration	Market
Ruconest™ / Rhucin®								
Ruconest™ (rhC1INH) (Europe)	Hereditary Angioedema							2010
Rhucin® (rhC1INH) (US)	Hereditary Angioedema							
rhC1INH “additional indications”								
rhC1INH	Antibody Mediated Rejection (Kidney)				2010/11			
rhC1INH	Delayed Graft Function (Kidney) Ischemia Reperfusion Injury							
Other Recombinant Products								
rhFibrinogen	Fibrinogen deficiency							
rhCollagen	Tissue repair							
hLactoferrin	Nutritional applications							




Focus Products/indications



Partnerships + risk sharing models for further development

Balance Sheet Cleanup

Reduction of debt & risk



Market Capitalisation Debt

Financial Highlights

	H1'10	YE'09
Liquidity position (€M)	9.8	2.3
Equity (€M)	11.4	13.3
Net cash used for operating activities (€M)	10.0	24.3
Costs (€M)	12.1	29.0
Net loss (€M)	28.0*	32.1
Convertible debt (€M)	12.0^	10.9
Number of shares outstanding	304,953,323^^	154,501,037

* Increased net loss stemming from securities issued to public and private bondholders

^ Remaining portion (€10.9M) of public convertible debt of 2007 will be cleared, paid or maturity re-confirmed to 2012 or a combination of these; additional private convertible debt of Jan 2010 is cleared.

^^ Current nr of outstanding shares 357,952,614

Deliverables

- EU filing of Ruconest in September 2009 
- EU distribution agreement for Ruconest 
- EU Positive opinion for Ruconest 
- US Partnership for Rhucin 
- EU launch for Ruconest **ongoing**
- US BLA submission Rhucin **ongoing**
- Debt restructuring **ongoing**
- Product portfolio focusing on C1-inhibitor **ongoing**



www.pharming.com

NYSE Euronext: PHARM